DelveInsight’s, “Type 1 Diabetes – Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Type 1 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Some of the Key Highlights for Type 1 Diabetes
- The Key Companies working in Type 1 Diabetes include Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, and many others
- The Key Therapies for Type 1 Diabetes include Teplizumab, Emricasan, VX-880, and many others
Major Players in Type 1 Diabetes
There are approx. 80+ key companies are developing therapies for Type 1 Diabetes. The companies which have their Type 1 Diabetes drug candidates in the most advanced stage, i.e preregistration include Provention Bio
Phases
DelveInsight’s report covers around 100+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued and inactive candidates
Route of Administration
Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Got queries? Click here to know more about the Type 1 Diabetes Pipeline
Type 1 Diabetes Overview
Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth. Importantly, insulin allows glucose to enter muscle and adipose cells, stimulates the liver to store glucose as glycogen and synthesize fatty acids, stimulates the uptake of amino acids, inhibits the breakdown of fat in adipose tissue, and stimulates the uptake of potassium into cells. Individuals with type 1 diabetes mellitus require life-long insulin replacement therapy. Without insulin, diabetic ketoacidosis (DKA) develops and is life-threatening.
Learn more by requesting for sample @ Type 1 Diabetes Pipeline
Type 1 Diabetes Key Companies
- Landos Biopharma
- Diamyd Medical
- Gan&Lee Pharmaceuticals
- Zealand Pharma
And many others
Type 1 Diabetes Therapies
- Teplizumab
- Emricasan
- VX-880
And many others
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Type 1 Diabetes
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Type 1 Diabetes Emerging Therapies
- Type 1 Diabetes Market Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Type 1 Diabetes Report Methodology
- DelveInsight Capabilities
- Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services